As of 2:10pm ET
| +0.21 / +5.11%|
The 4 analysts offering 12-month price forecasts for Cascadian Therapeutics Inc have a median target of 8.50, with a high estimate of 13.00 and a low estimate of 4.00. The median estimate represents a +96.76% increase from the last price of 4.32.
The current consensus among 5 polled investment analysts is to Buy stock in Cascadian Therapeutics Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.